Survodutide
Also known as · BI 456906
to clear
How a single dose clears, assuming first-order elimination. The half-life is the biggest driver of how often you dose — start a cycle to see your own cumulative concentration curve.
An investigational GLP-1/glucagon dual agonist studied for obesity and MASH (fatty liver). Not yet approved.
Combines GLP-1 appetite suppression with glucagon-driven energy expenditure and hepatic fat reduction.
Weekly subQ; trial titration up to ~6 mg.
Refrigerated; protect from light.
This page summarizes publicly available information. None of it constitutes medical advice, prescription, or recommendation to acquire, possess, or use any compound. Many peptides described are research chemicals not approved for human use in the EU. Consult a licensed physician.
Semaglutide
A long-acting GLP-1 receptor agonist for type-2 diabetes and weight management. Slows gastric emptying and suppresses appetite.
Tirzepatide
A dual GIP/GLP-1 receptor agonist with superior weight loss and glycemic control versus semaglutide in head-to-head trials.
Retatrutide
An investigational triple agonist (GIP/GLP-1/glucagon) showing the largest weight-loss figures yet in trials. Not yet approved.